Publication: What to expect from HER-2 directed therapies in advanced gastric cancer?
Loading...
Files
Date
Authors
Journal Title
Journal ISSN
Volume Title
Publisher
MARMARA UNIV, FAC MEDICINE
Abstract
Gastric cancer is the second most common cause of cancer related death worldwide. Over 20% of the advanced gastric cancer are considered to be HER-2 positive. Studies investigating the prognosis of HER-2 positive advanced gastric cancer revealed conflicting results. Trastuzumab, a monoclonal antibody against HER-2, has shown a significant clinical activity in HER-2 positive gastric cancer patients. In this review, I will briefly summarize the clinical studies of anti-HER-2 therapies performed in HER-2 positive gastric carcinoma.